A candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline exhibited an insufficient immune response in early-stage clinical trials, delaying the companies' vaccine development timeline, Reuters reports.
A candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline exhibited an insufficient immune response in early-stage clinical trials, delaying the companies' vaccine development timeline, Reuters reports.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.